Immunotherapy combo for colon cancer spread to the liver
Treatments studied
Part of Cancer clinical trials.
This trial is testing a combination of two drugs (pembrolizumab and odetiglucan) for people with colon or rectal cancer that has spread mainly to the liver. The goal is to see if this combination can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your cancer has spread mostly to the liver, with at least one measurable liver tumor.
- You have already tried certain standard chemotherapies and a targeted therapy (VEGF inhibitor), and if your tumor has no RAS/BRAF mutations, you have also tried an EGFR inhibitor.
- Your tumor is 'MMR proficient' or 'MSS' – meaning it doesn't have a specific genetic marker that makes it more likely to respond to immunotherapy alone.
- You are in good general health (able to care for yourself, up and about) and have a life expectancy of at least 3 months.
- You have not been treated with this type of immunotherapy (PD-1/PD-L1) before and have recovered from side effects of prior treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for people with colorectal cancer that has spread to the liver and cannot be removed by surgery. It aims to shrink or control these liver tumors.
This trial tests combinations of immunotherapy drugs for people with colorectal cancer that has spread to the liver and is scheduled for surgery. The goal is to see if these treatments are safe and effective before and after the operation.
This trial is testing a combination of a new immunotherapy drug (QL1706) with chemotherapy and either cetuximab or bevacizumab for people with colorectal cancer that has spread to the liver and can potentially be removed by surgery. The goal is to shrink the tumors before surgery, making them easier to remove.
This trial tests a combination of treatments for people with colorectal cancer that has spread to the liver and cannot be removed by surgery. It uses an oncolytic virus (which infects and kills cancer cells) along with radiation, chemotherapy, targeted therapy, and immunotherapy to try to shrink the liver tumors.
This trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus another drug (Bevacizumab) and chemotherapy (CAPEOX) for people with colorectal cancer that has spread to the liver. The goal is to shrink the tumors enough to allow surgery to remove them.
This trial tests a new combination of treatments for colorectal cancer that has spread to the liver. It combines a special type of radiation therapy (called PULSAR) with immunotherapy and chemotherapy plus a drug that targets blood vessels, to see if it helps shrink tumors and improve outcomes.
Hear when a new Colorectal Adenocarcinoma Metastatic in the Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.